News
News
New antifungal compound targets resistant fungi without kidney toxicity
Researchers have designed an antifungal compound that targets a molecular feature unique to fungi, showing activity against drug-resistant pathogens while avoiding kidney injury in preclinical studies.
3D Cell Painting reveals cancer drug differences missed in 2D
Two cancer drugs appeared almost identical in conventional screening, but a new 3D Cell Painting method exposed striking differences in their effects, raising questions about what 2D models might miss.
New TRPV1 study could change how painkillers are designed
Researchers have found that the TRPV1 pain receptor responds differently to individual stimuli, revealing functional differences that could help inform the development of more selective pain medicines.
MLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
Disrupting cell-wall transport could expose weakness in resistant bacteria
Researchers have identified a weakness in antibiotic-resistant bacteria that could help restore susceptibility to existing treatments by disrupting a lipid carrier essential for bacterial cell-wall synthesis.
Opinion and interviews
- Previous
- Next
Disrupting cell-wall transport could expose weakness in resistant bacteria
Researchers have identified a weakness in antibiotic-resistant bacteria that could help restore susceptibility to existing treatments by disrupting a lipid carrier essential for bacterial cell-wall synthesis.
Researchers solve 30-year mystery of key inflammatory enzyme gene
A gene responsible for producing a critical enzyme in inflammatory signalling has been identified after more than 30 years, with findings suggesting the pathway acts as both an immune alarm and a cellular shield with implications for cancer, IBD and asthma.
Bacterial microrobot platform achieves 82 percent tumour inhibition in bladder cancer
A hybrid microrobotic platform combining living bacteria, nanoparticles and targeted chemotherapy has achieved 82.4 percent tumour inhibition in preclinical bladder cancer models.
Self-driving labs and advanced cell models feature at ELRIG 2026
From self-driving laboratories to advanced cellular models, ELRIG Drug Discovery 2026 showcases technologies helping researchers generate better data, evaluate drug candidates and improve early discovery.
BCAT1 enzyme identified as fibrosis target after heart attack
Researchers at Nagoya University have identified BCAT1, an enzyme involved in proline supply for collagen synthesis, as a potential target for reducing cardiac fibrosis following myocardial infarction.
bit.bio launches refined human astrocyte model for neurotoxicity assessment
Cambridge biotech bit.bio has released ioAstrocytes 2.0, a genetically matched human astrocyte model designed to support functional neuroscience research and earlier assessment of seizure liability and neurotoxicity in drug development.
PacBio and TychoBio partner to advance AI-driven RNA therapies
PacBio and AI drug discovery company TychoBio are generating full-length RNA datasets from more than 10,000 samples to train AI models and accelerate the development of RNA therapies for rare diseases.
Speakers announced for Protein Sciences in Drug Discovery 2026 in Stevenage
Three leading scientists in protein science, structural biology and AI will headline the Protein Sciences in Drug Discovery conference at GSK Stevenage in November 2026, exploring advances in AI-driven drug design, native mass spectrometry and membrane protein folding.
Tazbentetol shows retinal neuroprotection potential in diabetic mouse model
Experimental synaptic restoration compound tazbentetol has demonstrated neuroprotective effects in the retinas of diabetic mice, offering a potential new therapeutic avenue for diabetic retinal neuropathy ahead of detectable vascular damage.
VPS34 inhibition boosts GD2 visibility to enhance neuroblastoma immunotherapy
Penn State researchers have shown that inhibiting the protein VPS34 increases GD2 display on neuroblastoma cell surfaces, making tumours more visible to anti-GD2 antibodies and improving outcomes in preclinical combination studies.
WhiteLab Genomics raises $26m to advance AI-designed genomic medicines
TechBio firm WhiteLab Genomics has closed a $26 million Series B round to expand in vivo validation of its AI-designed genomic medicines across viral and non-viral delivery platforms.
KRAS inhibition and CTLA-4 blockade could overcome gastric cancer immunotherapy resistance
Researchers have identified oncogenic KRAS as a key driver of immunosuppression in gastric adenocarcinoma.
New compound targets MAP4K4 pathway to combat fatty liver disease
An experimental small-molecule inhibitor targeting the MAP4K4 protein has reduced fat accumulation, inflammation, liver injury and fibrosis in preclinical models of MASH, offering a potential new therapeutic avenue for a disease with limited treatment options.
CMA restoration may clear senescent cells in ageing tissues
Researchers at Albert Einstein College of Medicine have identified a cellular recycling pathway whose age-related decline allows senescent ‘zombie’ cells to evade immune clearance.
MALVINA machine learning platform reveals how bacteria behave inside human cells
A new machine learning-based platform called MALVINA measures bacterial invasion, intracellular accumulation and DNA damage at single-cell resolution, exposing infection dynamics that conventional assays cannot detect.
ELRIG Drug Discovery 2026 celebrates 20th anniversary at ExCeL London
ELRIG Drug Discovery 2026 returns to ExCeL London for its 20th year, with AI, automation and advanced cell models among the technologies set to feature across the two-day programme.
Existing drug could target neuroinflammation across multiple brain disorders
Researchers at the University of Birmingham have identified the P2X7 receptor as a key driver of neuroinflammation in human brain tissue, raising the prospect of repurposing existing therapies to treat various brain conditions.
Synthetic protein targets TLR4 within membrane to curb inflammation
Scientists at Scripps Research have engineered a synthetic protein capable of binding to Toll-like receptor 4 within the cell membrane, reducing inflammatory signalling.
Insilico Medicine nominates AI-designed ISM1354 GIPR antagonist for obesity
Insilico Medicine has nominated ISM1354, an AI-designed small-molecule GIPR antagonist, as a preclinical candidate for obesity and related metabolic disorders.
AI consortium targets antibody developability prediction with 10,000-sequence dataset
A new industry consortium led by Ginkgo Datapoints and Apheris is assembling a 10,000-antibody dataset to train AI models that can flag developability problems earlier in the drug discovery pipeline.